NSE shares surge in unlisted market amid IPO buzz. Here's what analysts say
It may be noted that from FY22 to FY25, the exchange clocked a 33% compound annual growth in revenue to Rs 19,177 crore, while net profit surged at 36% CAGR to Rs 12,188 crore. For FY25 alone, net profit rose 47% to Rs 12,187.94 crore, with total income up 16.7% year-on-year. NSE also declared a Rs 35-per-share dividend, reinforcing its reputation as a consistent wealth generator.IS THERE FURTHER UPSIDE?advertisementSeveral analysts have suggested that the valuation gap with BSE suggests further upside, provided the NSE lists successfully. Prashanth Tapse, Senior VP (Research), Mehta Equities Ltd told Business Today that the IPO could unlock value. 'However, it hinges on regulatory clearance from Sebi. If a No Objection Certificate comes through, we could see another leg up in the unlisted price,' he added. At Rs 2,400 a share, NSE's implied market cap stands at around Rs 5.9 lakh crore. That makes it India's fifth most valuable company and the fifth largest stock exchange globally, after NYSE, Nasdaq, Shanghai, and Tokyo.The bullish outlook isn't just about the IPO. It's also about scale and dominance. NSE commands near-total control over Indian equity derivatives and substantial leads in other segments.In Q4FY25, it held 99.8% market share in equity futures, 94.6% in cash trading, 93.9% in currency derivatives, and 81.2% in equity options. Globally, it's the largest derivatives exchange by contract volume and second only to the NYSE in equity trades.Still, not everyone is gung-ho. Some market participants remain cautious given the stock's sharp rally and the lack of clarity on the IPO timeline.'The recent surge is speculative to some extent,' said Hitesh Dharawat of Dharawat Securities. 'Unless we get firm updates on listing, near-term volatility can't be ruled out,' he told Business Today.advertisementFor now, NSE's IPO remains one of the most anticipated events in the Indian capital markets. If regulatory hurdles are cleared and listing proceeds, early investors in the unlisted market could be sitting on a goldmine.(Disclaimer: The views, opinions, recommendations, and suggestions expressed by experts/brokerages in this article are their own and do not reflect the views of the India Today Group. It is advisable to consult a qualified broker or financial advisor before making any actual investment or trading choices.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
20 minutes ago
- Economic Times
Sebi floats consultation paper on prudential norms for derivatives on non-benchmark indices
Sebi issued a consultation paper on implementing new eligibility norms for derivatives on non-benchmark indices, proposing constituent limits and weight caps. Exchanges BSE and NSE favor adjusting existing indices with phased transitions to ensure smooth compliance. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Markets regulator Sebi on Monday issued a consultation paper on how to implement new eligibility norms for derivatives on non-benchmark indices . The paper follows a May 29 circular that mandated stricter prudential rules to ensure such indices remain broad-based and not overly per the circular, non-benchmark indices with derivatives must have at least 14 constituents, with the top constituent's weight capped at 20% and the combined weight of the top three limited to 45%. Weights must also follow a descending order across exchanges have been evaluating two options: Alternative A - Launch new indices that meet the criteria while continuing existing ones and Alternative B - Adjust the constituent structure and weights of existing which runs the Bankex index with 10 constituents and no ETF tracking, has preferred Alternative B, opting to adjust weights and constituents in one on the other hand, has two affected indices — Nifty Bank (12 constituents, Rs 34,251 crore AUM in ETFs) and Nifty Financial Services (20 constituents, Rs 511 crore AUM).After consulting with mutual funds and AMFI, NSE has also favored Alternative B, but recommended a phased glide-path approach to avoid disruptions, particularly given the large AUM in Nifty Bank the proposed glide path, adjustments in constituent weights would be carried out in up to four monthly tranches, ensuring a staggered and orderly has now invited comments from stakeholders on whether adjusting existing indices is the right approach and on the modalities of such weight adjustments. The deadline for submitting comments is September 8 via Sebi's online portal (link here) or through email.
Mint
22 minutes ago
- Mint
Indian drugmakers aim to boost exports to Mexico, South America's No. 2 pharma market
New Delhi: Indian drugmakers are in talks with Mexico for a simpler approval process as they seek to boost exports to the second-largest pharma market in South America, said two people aware of the matter. The Indian Drugs Manufacturers Association (IDMA) is intensifying its focus on Mexico, betting that the nation's complex drug approval process will be simplified, the people said on the condition of anonymity. Members of the association are in talks with officials from Mexico's ministry of economy and health regulator COFEPRIS (Federal Commission for the Protection against Sanitary Risks) to explore new rules and financial incentives, the people said. India seeks to significantly boost its medicine exports to Mexico, a market currently valued at over $20 billion and is expected to grow to $38.5 billion by 2033, according to a report by the International Market Analysis Research and Consulting Group. Domestic pharmaceuticals account for only $180 million. Indian drugmakers encounter challenges, primarily the lengthy and intricate regulatory hurdles set by COFEPRIS. India's pharmaceutical industry, the world's third largest by volume, is a global powerhouse with a diverse product base including generic drugs, vaccines, and biologics. In the fiscal year 2023-24, the market was valued at $50 billion, with exports accounting for $26.5 billion, according to the estimates provided by the Department of pharmaceuticals. Queries emailed to the Embassy of Mexico in New Delhi remained unanswered. "IDMA regularly participates in interactions with National Regulatory Agencies from various geographies," said Dr. Viranchi Shah, national spokesperson for IDMA. The talks reflect Mexico's increasing recognition of India as a reliable supplier of high-quality, affordable medicines. This push is part of a broader effort to strengthen the overall trade relationship between the two countries. While India's exports to Mexico have been growing, largely driven by the automobile and auto parts sectors, the pharmaceutical industry remains an underexplored avenue. Indian drug companies are keen to leverage Mexico's proximity to the US and its network of trade agreements to use it as a base for expanding into North and Central American markets. While a recent virtual meeting was postponed, an official familiar with the matter said IDMA is in contact with Mexican authorities to resolve the issues. This follows a similar meeting held a few months ago, indicating a consistent dialogue to streamline processes for Indian drug manufacturers. Mexico's pharmaceutical market, the second largest in Latin Americaafter Brazil and growth is fuelled by an ageing population and a rising prevalence of chronic diseases. For Indian companies, which are global leaders in generic drug production, a simplified regulatory path in Mexico could unlock a major new export corridor and diversify their international presence.
Hindustan Times
22 minutes ago
- Hindustan Times
India may impose 3-year tariff on top steel producers, China to feel impact
The Indian government may impose a three-year import tariff of 11–12 per cent on some selected steel products, if it heeds to a communique by its Directorate General of Trade Remedies (DGTR) on August 16. The recommendation is aimed at curbing rising shipments from top steel producers like China.(REUTERS) The proposed tariff on steel imports would begin at 12% in the first year, reduce to 11.5% in the second, and further drop to 11% in the third, Reuters reported. The move would curb rising shipments from top steel producers like China, whose oversupply has disrupted global markets. "The Authority concludes that there is a recent, sudden, sharp and significant increase in imports," the DGTR notification said, adding that this could cause serious injury to the domestic steel sector. This latest recommendation follows a temporary 12% safeguard duty imposed by India in April for 200 days after preliminary findings showed a steep increase in steel imports. The final recommendation now formalises the case for longer-term protection. Global steel glut behind tariff push The DGTR also said that due to 50% tariffs on steel imports into the US, coupled with similar measures by other countries, a bulk of steel volumes are lying with manufacturers across the world. "Therefore, the safeguard duty must address, not only the serious injury suffered by the domestic also the threat of serious injury that is likely to arise in the future." Trade tensions on the rise as global steel tariffs tighten The recommendation comes amid a wave of international trade protection against Chinese steel exports. US President Donald Trump's import tariffs on steel have fuelled a wave of trade frictions against Chinese steel, with countries including South Korea and Vietnam imposing anti-dumping levy. In a related move, Japanese steel industry lobby groups have also called for faster action to prevent evasion of anti-dumping duties and protect their domestic markets from unfair imports.
